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MyoD is a master regulator of myogenesis with a potent ability to redirect the cell fate of even terminally
differentiated cells. Hence, enhancing the activity of MyoD is an important step to maximising its po-
tential utility for in vitro disease modelling and cell replacement therapies. We have previously shown
that the reprogramming activity of several neurogenic bHLH proteins can be substantially enhanced by
inhibiting their multi-site phosphorylation by proline-directed kinases. Here we have used Xenopus
embryos as an in vivo developmental and reprogramming system to investigate the multi-site phospho-
regulation of MyoD during muscle differentiation. We show that, in addition to modiﬁcation of a pre-
viously well-characterised site, Serine 200, MyoD is phosphorylated on multiple additional serine/
threonine sites during primary myogenesis. Through mutational analysis, we derive an optimally active
phospho-mutant form of MyoD that has a dramatically enhanced ability to drive myogenic reprog-
ramming in vivo. Mechanistically, this is achieved through increased protein stability and enhanced
chromatin association. Therefore, multi-site phospho-regulation of class II bHLH proteins is conserved
across cell lineages and germ layers, and manipulation of phosphorylation of these key regulators may
have further potential for enhancing mammalian cell reprogramming.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The basic-Helix-Loop-Helix (bHLH) protein MyoD is an exten-
sively studied Muscle Regulatory Factor (MRF) that plays a pivotal
role during muscle development, and has also received much
attention for its ability to direct a myogenic program even in
terminally differentiated somatic cells [1,2]. Using MyoD to direct
trans-differentiation has potential utility in cellular reprogramming
efforts directed at in vitro modelling of muscle diseases for drug
screening [3] and in cell replacement therapies [4]. However,
reﬁning of these reprogramming methods requires optimising the
myogenic activity of MyoD.
We have previously studied other master regulatory proneuralk, cyclin-dependent-kinase;
actor; SP, serine-proline; TP,
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r Inc. This is an open access articlebHLH transcription factors that drive differentiation in the neural
lineage, namely Neurogenin2, Ascl1 and NeuroD4 [5e8]. We see
that phosphorylation of these factors on multiple serine-proline
and threonine-proline (SP and TP) sites suppressed both their
ability to drive neuronal differentiation during development [5,7]
and during cellular reprogramming of mammalian cells [6].
MyoD phosphorylation on Serine 200 (S200) and S5, sites both
found as part of an SP motif, has long been recognised to underlie
the characteristic MyoD protein ﬂuctuations and activity that vary
with cell cycle phase in proliferating myoblasts [9e13]. MyoD also
contains multiple additional SP and TP sites which may, by analogy
with proneural factors, play an additional role in regulation of the
ability of MyoD to promote myogenic conversion and differentia-
tion. Here, using the Xenopus tadpole as a model to test MyoD's
myogenic conversion potential, we show that myogenic activity of
MyoD is regulated by up to ﬁve S/TP kinase sites speciﬁcally located
in the C terminus of the protein. Furthermore, we see that multi-
site phosphorylation regulates both MyoD protein stability and
chromatin association. Finally, we identify an optimal phospho-
mutant form of MyoD that dramatically enhances myogenic con-
version of embryonic ectoderm in vivo.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Cloning
Wild-type (WT)mouseMyoD in pCS2 has been described [14]. A
single C terminal HA tag was added by PCR using the primers:
50GATCGGATCCACCATGGAGCTTCTATCGCCG-30;
50GATCCTCGAGTCAAGCGTAATCTGGAACATCGTATGGGTAAAGCAC-
CTGATAAATCGCATT-30. All single or multiple site mutations were
performed using the QuikChange II or QuikChange Multi Site-
Directed Mutagenesis Kit (Agilent Technologies) respectively (PCR
primers available on request). Nucleotide and protein sequence
alignments were conducted using ClustalW software [15].
2.2. Xenopus laevis embryo manipulation
Acquisition of Xenopus laevis embryos, preparation and injection
of synthetic mRNA, staging of embryos and in situ hybridisation
(ISH) were conducted as described previously [6,16,17]. Dig-
oxigenin-labelled anti-sense probes were synthesised from line-
arised plasmid Actc1 in pSP64T (Xenbase; EcoR1, SP6). Semi-
quantitative scoring was conducted for Muscle Actin staining on
the injected side of the embryo relative to the uninjected side;
grades were assigned 0e3, where 0 indicates no increase in myo-
genesis, through to 3 indicating extensive myogenesis.
2.3. Quantitative real-time PCR (qRT-PCR)
Whole embryo RNA was extracted using the Qiagen RNeasy®
Mini Kit and cDNAs were prepared with the QuantiTect® Reverse
Transcription Kit (Qiagen). qPCR analysis was conducted using the
Quantifast® SYBR Green PCR Kit (Qiagen) in a LightCycler® 480
(Roche). Thermal cycling parameters are described in Ref. [5], and
primer sequences (50e30): EF1aF ¼ CACCATGAAGCCCTTACTGAG;
EF1aR ¼ TGATAACCTGTGCGGTAAATG; xMyh4F ¼ GAA-
CAAGGACCCACTGAACG; xMyh4R ¼ TCCACCTTTACCAGCAGCAT.
2.4. Western blotting
Protein extracts were prepared from whole embryos and incu-
bated with or without lambda protein phosphatase (NEB) as
described [7], prior to separation on an 18% Tris/Glycine/SDS gel by
standardmethods. For assay of chromatin association, cross linking,
cytoplasmic and chromatin fractionation, western blot and protein
quantiﬁcation were conducted as described [7].
2.5. Statistical analysis
For western blotting, experiments were performed in inde-
pendent duplicate with representative results shown. For qPCR
data, mRNA expression was normalised to expression of the
housekeeping gene Elongation Factor 1a (EF1a), and for analysis,
mRNA levels in injected embryos were calculated relative to stage-
matched uninjected controls. Mean values and the standard error
of the mean (s.e.m.) were calculated from at least three indepen-
dent experiments (n ¼ 3). Statistical signiﬁcance was determined
using a paired two-tailed Student's t-test with (p < 0.05) ¼ *;
(p < 0.025) ¼ **; (p < 0.0125) ¼ ***. For in situ hybridisation data,
experiments were conducted in independent duplicate or triplicate
and the n numbers reported refer to the range of total numbers of
embryos in each injection category. Statistical signiﬁcance was
determined between categories using a Fisher's Exact Test for
Count Data, and p values are as described above.3. Results
3.1. MyoD is phosphorylated on sites in addition to S200 during
Xenopus primary myogenesis
Early studies investigating phospho-regulation of MyoD largely
focused on its modiﬁcation in proliferating cells in culture; either
C2C12 myoblasts or C3H10T1/2 ﬁbroblasts transfected with MyoD
[10,12]. To investigate phosphorylation of MyoD and its reprog-
ramming activity in vivo, we chose the highly versatile Xenopus
embryo system, which can be used to study mammalian MyoD
activity both in the endogenous myotome and also for reprog-
ramming activity in the non-myogenic ectoderm tissue [14].
Furthermore, the ﬁrst cleavage of the fertilised egg bisects the
embryos into future left and right sides, so unilateral mRNA in-
jection allows MyoD activity to be directly compared between
injected and uninjected embryo sides.
Firstly, we explored whether MyoD is phosphorylated during
primary myogenesis. Extracts were prepared from stage 12.5 em-
bryos injected with mRNA encoding HA-tagged Wild-Type (WT)
MyoD, or S200A MyoD, a mutant version with S200 mutated to
alanine to prevent phosphorylation at this established site.Western
blot analysis reveals a broad protein band for both WT and S200A
proteins (Fig. 1A), with more S200A protein than WT, consistent
with previous reports that demonstrate a longer half-life for this
mutant protein [10e12]. Incubation with a broad spectrum protein
phosphatase enhances the migration of both WT and S200A, indi-
cating phosphorylation on at least one additional site during dif-
ferentiation in vivo.
3.2. A multi-site phospho-mutant MyoD promotes enhanced
myogenesis in vivo
Mouse MyoD protein contains seven potential proline-directed
kinase sites (six serine-proline (SP), and one threonine-proline
(TP)) that are highly conserved with human MyoD
(Supplementary Fig. 1). To further explore a potential regulatory role
of S/TP sites additional to S200 during myogenesis, a panel of
phospho-mutant forms of MyoD were created (Fig. 1B): 7T/S-A
MyoD contains all seven SP/TP sitesmutated to alanine-proline (AP),
while 6T/S-A(S200) has the S200 site restored but the remaining six
sites mutated. In order to compare their myogenic activity, mRNA
encoding these proteins was injected unilaterally into two-cell stage
Xenopus embryos, and myogenesis was assayed in stage 18 embryos
by RT-qPCR and in situ hybridisation (ISH) for muscle structural
genes Myosin Heavy Chain or Muscle Actin respectively (Fig. 1CeE).
At this level of over-expression, WT MyoD induces a small increase
in myogenesis, largely conﬁned to expansion of themyotome on the
injected side. By comparison, both S200A and full phospho-mutant
7T/S-A induce a marked increase in myogenesis spreading laterally,
and demonstrating reprogramming of ectoderm tissue. Interest-
ingly, 6T/S-A(S200) also induces a signiﬁcant increase inmyogenesis
relative to WT MyoD, albeit with less activity than S200A or 7T/S-A
MyoDs. This demonstrates that sites in addition to S200 can regulate
myogenic activity of MyoD.
3.3. Regulatory activity resides in C terminal phosphorylation sites
We have previously described a model for phospho-regulation
of proneural protein activity, where the number, rather than loca-
tion of available phospho-sites is the key determinant of bHLH
activity; mutation of increasing numbers of phosphorylation sites
additively increases the neurogenic activity of the mutant proteins
Fig. 1. MyoD is phospho-regulated on sites in addition to S200 during primary myogenesis. (A) Western blot analysis of protein extracts from stage 12.5 embryos injected with
200 pg mRNA encoding HA-tagged WT or S200A-MyoD. Samples were incubated with or without lambda protein phosphatase. Tubulin provided a loading control. (B) Schematic
representation of WT mouse MyoD protein and phospho-mutant variants, showing approximate locations of SP/TP sites that are mutated to AP in each. (CeE) Embryos were
unilaterally injected at the 2-cell stage with 100 pg mRNA encoding the respective MyoD constructs. At stage 18, embryos were assayed by RT-qPCR for Myosin Heavy Chain
expression (C [n ¼ 3]) or by ISH with semi-quantitative scoring for Muscle Actin expression (D [n ¼ 52e73]) as described in the methods. Representative embryos are shown in (E);
injected side to the right. * ¼ (p < 0.05); ** ¼ (p < 0.025); *** ¼ (p < 0.0125).
L.J.A. Hardwick et al. / Biochemical and Biophysical Research Communications 481 (2016) 97e103 99[5,7]. To explore if a similar phenomenon may control regulation of
MyoD, a panel of MyoD phospho-mutants were made with SP/TP
sites cumulatively mutated from the N terminus to generate 1S-A,
2S-A etc (Fig. 2A). Due to the immediate proximity of T296/S298,
these sites were mutated simultaneously.
Embryos were injected with mRNA as before and scored for
myogenesis at stage 18 by ISH (Fig. 2BeC). Mutation of the N ter-
minal SP sites in MyoD has no signiﬁcant effect on its activity rela-
tive to the wild-type protein. Similarly, mutation of S200 in addition
to the two N terminal sites (i.e. 3S-A) produces a level of myogenesis
comparable to mutation of the single S200 site alone, suggesting
that the N terminal sites do not contribute to regulation of MyoD
myogenic activity. However, mutation of C terminal residues in
addition to S200 results in a more active MyoD than the single
phosphorylation site mutant S200A MyoD. Thus, for MyoD, both
number and location of phospho-sites contribute to its regulation.3.4. S200 is the most important individual C terminal site for
regulating myogenic activity
The ﬁve C terminal phospho-sites in mouse MyoD are also the
phospho-sites that are most conserved with both human andXenopus MyoD (Supplementary Fig. 1); S200 and S262 are highly
conserved between all three species, suggesting that these may
have enhanced functional signiﬁcance. We therefore sought to
address whether myogenic activity depends on any particular C
terminal phospho-site.
Each C terminal site was mutated individually and myogenic ac-
tivity was assayed as described above (Fig. 2DeE). Mutation of any
individual C terminal phospho-site results in signiﬁcantly enhanced
myogenesis compared to WT MyoD. Furthermore, the three most C
terminal sites when mutated individually (S262, S277 and T296/
S298)areverysimilar toeachother in inducingamoderate increase in
myogenesis. Bycomparison,mutationof theS200 site alone results in
myogenic activity that is signiﬁcantly greater than any other single
site mutant, yet this is still not as active as the full 7T/S-A phospho-
mutant. Therefore, S200 confers the most signiﬁcant regulatory ac-
tivity but its mutation alone is not sufﬁcient to maximally activate
MyoD; additional C terminal residues must also be mutated.3.5. Identiﬁcation of an optimal phospho-mutant MyoD with
maximal myogenic activity
For the purposes of cellular reprogramming, an optimal form
Fig. 2. Mutational analysis shows regulatory activity of S200 and additional C terminal phosphorylation sites. Schematic representation of phospho-mutant constructs with
mutation of cumulative (A) or individual (D) sites. Two-cell stage embryos were unilaterally injected with 100 pg mRNA of the respective MyoD construct and assayed at stage 18 for
expression of Muscle Actin by ISH: (B) Cumulative mutant series [n ¼ 68e74] with representative images shown in (C). (D) Single site mutants [n ¼ 52e83]. NS ¼ Not signiﬁcant;
* ¼ (p < 0.05); ** ¼ (p < 0.025); *** ¼ (p < 0.0125).
L.J.A. Hardwick et al. / Biochemical and Biophysical Research Communications 481 (2016) 97e103100of MyoD would have maximal activity in driving myogenic
conversion of non-muscle tissue. Therefore, we ﬁnally sought to
derive an optimal phospho-mutant MyoD in our Xenopus assay.
For the proneural proteins, maximal activity is achieved by
mutation of all available phospho-sites [5e7], but for MyoD, we
see that N terminal sites do not contribute to regulation (Fig. 2).
S200 is the most important single C terminal site (Fig. 2), so
additional constructs were made to mutate S200 in combination
with other C terminal sites (data not shown). In all assays con-
ducted, the most extensive myogenesis is induced by CT 5T/S-A
MyoD, in which all ﬁve C terminal phospho-sites are mutated
but the two N-terminal phospho-sites are intact. These results
are summarised in Fig. 3, where NT 2S-A MyoD shows equiva-
lent activity to WT protein, and CT 5T/S-A MyoD is more active
than the full 7T/S-A phospho-mutant. We note that both of these
multi-site mutants are signiﬁcantly more active than the single
S200A mutant, inducing extensive conversion of the lateral
ectoderm to a myogenic cell fate, often seen bilaterally over the
embryo. Thus, while S200 shows the greatest regulatory role of
any individual site, phosphorylation must be prevented on all
ﬁve C-terminal serine/threonines for maximal differentiation
activity.3.6. CT 5T/S-A MyoD has both increased protein accumulation and
enhanced chromatin binding relative to WT and S200A MyoD
Having established an optimal phospho-mutant form of MyoD
that has superior myogenic activity in vivo, we investigated the
mechanisms by which this enhanced differentiation is achieved.
One mechanism may be by enhancing MyoD protein stability. We
have already shown that injection of equal amounts of WT and
S200A MyoD mRNA produces a greater accumulation of S200A
protein relative to WT MyoD (Fig. 1) so we next determined
whether the optimal phospho-mutant CT 5T/S-A MyoD showed
further enhancement of stability. HA-tagged mRNA was injected
into Xenopus embryos, and protein extracts were prepared at stage
12.5 for western blot analysis; the density of each MyoD protein
band was calculated relative to the respective tubulin loading
control (Fig. 4A, C). While injection of the same amount of mRNA
results in an almost three-fold increase in S200A protein relative to
WT MyoD, CT 5T/S-A MyoD protein accumulates to a level that is
more than four-fold higher than WT MyoD. Thus, whilst S200 is an
established phospho-site that regulates MyoD stability [10,12],
further enhancement of MyoD protein stability accompanies mu-
tation of additional C-terminal SP sites.
Fig. 3. Maximal myogenic activity is achieved by mutation of multiple C terminal sites. (A) Schematic representation of phospho-mutant constructs. (B) Two-cell stage embryos
were unilaterally injected with 100 pg mRNA of the respective MyoD construct and assayed at stage 18 as before [n ¼ 32e41] with representative images shown in (C). NS ¼ Not
signiﬁcant; * ¼ (p < 0.05); ** ¼ (p < 0.025); *** ¼ (p < 0.0125).
Fig. 4. CT 5T/S-A MyoD shows enhanced protein stability and enhanced chromatin binding relative to both WT and S200A MyoD. Embryos were injected with 200 pg mRNA
encoding HA-tagged MyoD constructs as indicated, and western blot analysis was performed on whole embryo extracts at stage 12.5 (A) or cross linking and cytoplasmic/chromatin
extracts at stage 13 (B). MyoD protein density was quantiﬁed relative to tubulin loading control for whole embryo extracts (C) and cytoplasmic fractions (D), or relative to histone H3
for chromatin fractions (D). Mean values are shown from independent duplicate samples with standard error of the mean.
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stability compared to their wild-type counterparts, but also exhibit
enhanced DNA binding afﬁnity, and both of these attributes
contribute to superior reprogramming activity [5,7]. To test
whether MyoD phospho-status inﬂuences protein binding toembryonic chromatin, embryos were injected as before, and cross-
linking was performed in stage 13 embryos prior to nuclear
extraction, chromatin isolation and western blot analysis (Fig. 4B,
D). Cytoplasmic samples were also collected and MyoD protein
accumulation was calculated relative to tubulin or histone H3
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tively. The absence of tubulin protein in the chromatin fraction
conﬁrms successful chromatin isolation, and no MyoD protein was
detected in the uninjected embryos, conﬁrming speciﬁcity of the
anti-HA antibody.
Comparing the relative amounts of chromatin bound MyoD
protein (Fig. 4D) with the relative amounts of whole embryo MyoD
protein (Fig. 4C), S200A MyoD is only 1.6-fold higher than WT
MyoD in chromatin samples, suggesting that S200A displays
greater protein stability than WT MyoD, but no greater chromatin
binding afﬁnity. Therefore, protein stability alone contributes to the
enhanced activity of this mutant S200A protein. In contrast,
chromatin-bound CT 5T/S-A MyoD accumulates to ﬁve-fold higher
than WT and three-fold higher than S200A MyoD, demonstrating
an increased chromatin binding afﬁnity in addition to increased
protein accumulation. Thus, our optimal phospho-mutant CT 5T/S-
A dramatically enhances myogenesis in vivo by a combination of
increased protein accumulation and enhanced chromatin binding;
this latter feature being unique to the CT 5T/S-A MyoD phospho-
mutant and not shared with S200A MyoD.
4. Discussion
The bHLH transcription factor MyoD is a master regulator of
myogenesis, and manipulating its activity both for in vitro model-
ling of muscle disease and for cell replacement therapy has huge
potential in translation medicine and cellular reprogramming [18].
We set out to engineer a maximally active form of MyoD for in vivo
reprogramming in the Xenopus frog system. Neurogenin2, Ascl1
and NeuroD4, bHLH transcription factors regulating neurogenesis,
undergo multi-site phosphorylation that coordinates neuronal
differentiation with the cellular kinase environment in vivo [5e8].
As such, multi-site bHLH protein phosphorylation in rapidly
dividing cells suppresses their ability to drive neuronal differenti-
ation; a multiply phospho-mutant form of these proneural proteins
substantially enhances their ability to reprogram both Xenopus
ectoderm and mammalian ﬁbroblasts into neurons [5e8]. Here, we
show here that multi-site phosphorylation also controls the ability
of MyoD to regulate cellular reprogramming to muscle in vivo,
demonstrating conservation of a similar regulation of bHLH pro-
teins across cell lineages and germ layers.
Analogous to our ﬁndings for proneural bHLH proteins [5e8],
we see that MyoD is phospho-regulated on multiple proline-
directed kinase sites during developmental myogenesis. More-
over, by combining mutational analysis with this in vivo assay
system, we have identiﬁed an optimal phospho-mutant form of
MyoD, CT 5T/S-A MyoD, that displays markedly enhanced ability to
drive myogenic differentiation compared to any previously
described phospho-mutant [9e13]. Our optimal C terminal
phospho-mutant protein displays increased protein stability rela-
tive to both WT MyoD and S200A MyoD, a mutant previously
shown to have enhanced stability and activity compared to the WT
protein [10e12]. In addition, we also see that CT 5T/S-A MyoD has
increased chromatin afﬁnity that is not shared by S200AMyoD. The
data we present here, in combination with previous work on pro-
neural proteins [5e8], support the conservation of a phospho-
regulatory model of bHLH protein action, both functionally and
mechanistically, across both nerve and muscle cell lineages.
However, in contrast to proneural proteins where only the
number of available phospho-sites is key to regulating protein
function [5e8], we ﬁnd that both number and location of phospho-
sites are important for MyoD, with regulatory phospho-sites
located solely in the C terminus of the protein. In contrast to
MyoD N terminal phospho-sites, C terminal sites show strong
sequence conservation between species. Indeed, even inproliferatingmyoblasts, fourmajor isoforms ofMyoDwere found to
be subsequently resolved by phosphatase treatment [10], and an
early in vitro assay found increased reporter transactivation when
other individual C terminal proline-directed kinase sites were
mutated [12]. These were found not to be phosphorylated by cdks
in dividing culture cells, but they may be targeted by other proline-
directed kinases such as MAPKs in the environment of the differ-
entiating myotome.
The distinct C terminal location of regulatory phospho-sites may
also relate to the complexity of MyoD function that is being
revealed by genome-wide analysis. MyoD temporally orchestrates
expression of multiple subsets of genes during the speciﬁcation and
differentiation stages of myogenesis [19]. Additionally, MyoD has
been found to bind at sites throughout the genome where it in-
duces histonemodiﬁcations rather than gene expression [20]. Thus,
for MyoD, DNA binding afﬁnity does not always correlate with
transcriptional activation and instead, the timing and location of
cofactor association may be the critical determinant for temporal
and spatial activity. For example, genome-wide analysis has shown
that MyoD transcriptional activity is temporally regulated through
a direct repression of promoter-bound MyoD [19]. A comparison of
the genome-wide promoter occupancy of both WT and phospho-
mutant MyoD may reveal clues as to potential differential
phospho-regulation of distinct downstream MyoD targets.
Furthermore, consistent with a role in cofactor association, the
ability of MyoD to activate transcription in inaccessible chromatin
has been mapped to the C terminal domain [21], and partly
attributed to the helix 3 domain [22] that enables binding to
pioneer factors Pbx/Meis [23]; spanning resides 218e269, this in-
cludes the S262 phospho-site. It will be interesting to determine
whether co-factor binding is regulated by MyoD phosphorylation.
In conclusion, we have characterised multi-site phospho-regu-
lation of MyoD on C-terminal S/TP sites that controls its ability to
drive myogenesis in vivo: Whilst there are differences between the
myogenic and neurogenic bHLH factors, the essence of multi-site
phospho-regulation is both functionally and mechanistically
conserved in muscle and nerve. Using an in vivo developmental and
reprogramming assay system in Xenopus embryos, we have derived
a novel C terminal phospho-mutant MyoD protein that has signif-
icantly enhanced myogenic activity compared to any previously
described mutants. This has the potential for enhancing trans-
differentiation of mammalian cells into muscle for translational
applications, and this should form the basis of further
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